20/20 BIOLABS INC
AIDXNASDAQTrading Snapshot
- Day Range
- $0.41 – $0.42
- 52-Week Range
- $0.40 – $50.00
- Volume
- $2.00B
- Avg Volume
- $2.24B
- Shares Outstanding
- 12.3M
- Next Earnings
- Nov 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $730,571
- P/E Ratio
- -0.6
- P/S Ratio
- 2.6x
- EPS (TTM)
- $-0.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +116.3%
Why Investors Own AIDX
- ✓High-growth profile — revenue up +29.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
20/20 BIOLABS INC
AIDX
StockOtter · stockotter.spaceAbout 20/20 BIOLABS INC
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar t
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
CEO Jonathan Cohen to Detail the Company's Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Co
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy